Ireland launches regenerative medicine research center

Article Abstract:

On January 12, the National University of Ireland (Galway) received approximately 15 million pounds from the Irish government, which will be spread over a period of five years for building a new research center called Regenerative Medicine Institute (REMEDI, Galway). Faster commercialization of the results of the research could take place due to the grant-giving scheme but it will be important to maintain a balance between the various public incentives in order to optimize the output of R&D.

Financial management, Ireland, Finance, Company financing, National University of Ireland, Cork

---

China steps up US biotech intellectual property land grab

Article Abstract:

The non-healthcare Chinese firms are turning their attention towards the life sciences. The delegates from various industrialists are approaching U.S. research institutions to organize the intellectual property (IP) into tangible assets for technology transfer as the Chinese government is encouraging basic research and patent efforts in healthcare and biotech field.

United States, China, Government domestic functions, Patents & copyrights, Commercial physical research, Biological products exc. diagnostic, Biotechnology industry, Biotechnology industries, Science and technology policy, Intellectual property, Technology transfer

---

First Parkinson gene therapy trial launches

Article Abstract:

The first Parkinson gene therapy performed at New York Weill Cornell medical center aims at curing brain disorders. In the trial doctors aimed for the subthalamus area of the brain that may mediate symptoms of the disease.

Gene therapy, Parkinson's disease, Parkinson disease, Brain diseases

Similar abstracts:

• Abstracts: Beyond psychophysics: the need for a cognitive engineering approach to setting limits in manual lifting tasks
• Abstracts: Proposed 409A regulations: Part 1: Deferred compensation subject to 409A. Proposed regulations on adjustments to NUBIG
• Abstracts: Reverse mergers attract top-tier biotechs in sluggish IPO market. More biotechs gamble on convertibles

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.